CS Diagnostics Corp. (OTCQB: CSDX) Accelerates Global Expansion with Key Regulatory Milestones and Record Growth
CS Diagnostics Corp. (OTCQB: CSDX) announced significant progress across multiple fronts, including regulatory advancements for its flagship products and strong financial growth. The company's CS-Protect Hydrogel is under FDA review and has initiated patent filings in multiple countries. Their protective solution MEDUSA has secured authorization in the UAE and Europe, with EPA review ongoing in the US.
CSI, their subsidiary, reported a 75% increase in turnover for 2025 compared to 2024's $3.5 million. CSDX is launching a Regulation D offering and plans to become fully SEC-reporting by end of September 2025. The company is preparing for European market entry with MEDUSA shipments scheduled for October 2025.
CS Diagnostics Corp. (OTCQB: CSDX) ha annunciato progressi significativi su diversi fronti, tra cui avanzamenti normativi per i suoi prodotti di punta e una crescita finanziaria sostenuta. Il CS-Protect Hydrogel è attualmente al vaglio della FDA e ha avviato la registrazione di brevetti in più paesi. La loro soluzione protettiva MEDUSA ha ottenuto l’autorizzazione negli EAU e in Europa, con la revisione da parte dell’EPA in corso negli Stati Uniti.
La controllata CSI ha registrato un aumento del 75% del giro d’affari per il 2025 rispetto ai 3,5 milioni di dollari del 2024. CSDX sta lanciando un’offerta Regulation D e punta a diventare completamente quotata alla SEC entro la fine di settembre 2025. L’azienda si sta preparando per l’ingresso nel mercato europeo con le spedizioni di MEDUSA previste per ottobre 2025.
CS Diagnostics Corp. (OTCQB: CSDX) anunció avances significativos en múltiples frentes, entre ellos progresos regulatorios para sus productos insignia y un sólido crecimiento financiero. El CS-Protect Hydrogel está en revisión por la FDA y ha iniciado trámites de patentes en varios países. Su solución de protección MEDUSA ha obtenido autorización en los EAU y en Europa, con revisión de la EPA en curso en EE. UU.
La filial CSI reportó un aumento del 75% en el volumen de negocios para 2025 en comparación con los 3,5 millones de dólares de 2024. CSDX está lanzando una oferta Regulation D y planea convertirse en entidad que reporta a la SEC por completo a finales de septiembre de 2025. La empresa se está preparando para la entrada al mercado europeo con envíos de MEDUSA programados para octubre de 2025.
CS Diagnostics Corp. (OTCQB: CSDX)는 주력 제품에 대한 규제 진전과 강한 재무 성장을 포함해 여러 분야에서 상당한 진전을 발표했습니다. CS-Protect Hydrogel은 FDA 심사를 받고 있으며 다수의 국가에서 특허 출원을 시작했습니다. 그들의 보호 솔루션 MEDUSA는 UAE와 유럽에서 승인을 받았고, 미국에서는 EPA 심사가 진행 중입니다.
자회사 CSI는 2024년 3,500,000달러 대비 2025년 매출액이 75% 증가했다고 보고했습니다. CSDX는 Regulation D 발행을 시작하고 2025년 9월 말까지 SEC 보고 의무를 완전히 이행하는 것을 목표로 하고 있습니다. 또한 유럽 시장 진입을 준비 중이며 2025년 10월 MEDUSA 선적이 예정되어 있습니다.
CS Diagnostics Corp. (OTCQB: CSDX) a annoncé des progrès importants sur plusieurs fronts, notamment des avancées réglementaires pour ses produits phares et une forte croissance financière. Le CS-Protect Hydrogel est à l’examen par la FDA et des dépôts de brevets ont été lancés dans plusieurs pays. Leur solution de protection MEDUSA a obtenu l’autorisation aux Émirats arabes unis et en Europe, avec une révision par l’EPA en cours aux États-Unis.
La filiale CSI a enregistré une croissance de 75 % du chiffre d’affaires pour 2025 par rapport aux 3,5 millions de dollars de 2024. CSDX lance une offre Regulation D et prévoit de devenir entièrement déclarée à la SEC d’ici fin septembre 2025. L’entreprise se prépare à pénétrer le marché européen avec des expéditions de MEDUSA prévues pour octobre 2025.
CS Diagnostics Corp. (OTCQB: CSDX) meldete bedeutende Fortschritte in mehreren Bereichen, darunter regulatorische Fortschritte für seine Flaggschiffprodukte und ein starkes finanzielles Wachstum. Der CS-Protect Hydrogel befindet sich in der FDA-Prüfung und es wurden Patentanmeldungen in mehreren Ländern eingereicht. Die schützende Lösung MEDUSA hat in den VAE und Europa Zulassungen erhalten, während die EPA-Bewertung in den USA noch läuft.
Die Tochtergesellschaft CSI verzeichnete für 2025 einen Umsatzanstieg von 75% gegenüber den 2024 erzielten 3,5 Mio. USD. CSDX wird ein Regulation-D-Angebot starten und plant, bis Ende September 2025 vollständig SEC-berichtsPflichtig zu werden. Das Unternehmen bereitet den Markteintritt in Europa vor, mit MEDUSA-Lieferungen im Oktober 2025.
CS Diagnostics Corp. (OTCQB: CSDX) أعلنت عن تقدم كبير في عدة جبهات، بما في ذلك التقدمات التنظيمية لمنتجاتها الرائدة ونمو مالي قوي. CS-Protect Hydrogel يخضع لمراجعة FDA وبدأت طلبات براءات الاختراع في عدة دول. كما أن الحل الواقي MEDUSA حصل على ترخيص في الإمارات العربية المتحدة وأوروبا، مع مراجعة EPA جارية في الولايات المتحدة.
أبلغت شركة CSI التابعة عن زيادة بنسبة 75% في الإيرادات في 2025 مقارنة بـ 3.5 مليون دولار في 2024. ستطلق CSDX عرض Regulation D وتخطط لأن تصبح من حيث الإبلاغ مكتملة لدى SEC بحلول نهاية سبتمبر 2025. الشركة تستعد لدخول السوق الأوروبي مع شحنات MEDUSA المقررة في أكتوبر 2025.
CS Diagnostics Corp. (OTCQB: CSDX) 在多方面取得显著进展，包括其旗舰产品的监管推进和强劲的财务增长。其CS-Protect Hydrogel正在接受FDA审评，并已在多国启动专利申请。其防护解决方案MEDUSA已在阿联酋和欧洲获得授权，美国EPA评审正在进行中。
其子公司CSI报告称，2025年营业额较2024年的350万美元增长了75%。CSDX将启动D条例（Regulation D）融资，计划在2025年9月底前全面实现向SEC披露信息。公司正为进入欧洲市场做准备，MEDUSA的发货计划在2025年10月。
- 75% increase in turnover for 2025 compared to 2024's $3.5M baseline
- MEDUSA product received full authorization in UAE and Europe
- CS-Protect Hydrogel patent applications filed in multiple strategic countries
- Upcoming transition to become fully SEC-reporting company
- Strong demand for MEDUSA from hospitals, hotels, and schools
- FDA approval for CS-Protect Hydrogel still pending
- EPA authorization for MEDUSA in US market still under review
- Additional capital needed through Regulation D offering for expansion
CHEYENNE, WY / ACCESS Newswire / September 24, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) ("CSDX" or "the Company"), a pioneering leader in innovative diagnostic and protective solutions, today announced a series of transformative advancements as it resumes full-scale operations. With groundbreaking progress on its flagship products, CS-Protect Hydrogel and MEDUSA, alongside a strategic capital raise and enhanced financial reporting, CSDX is poised to capture significant market share in the U.S. and international arenas.
"As we resume our regular business activities, I am thrilled to update our shareholders and partners on the remarkable progress of our group's initiatives" said the President of CS Diagnostics Corp. "These developments underscore our commitment to innovation, regulatory excellence, and sustainable growth, setting the stage for an exciting new chapter in our journey."
CSDX's CS-Protect Hydrogel is advancing rapidly toward market readiness. The Company's application with the U.S. Food and Drug Administration (FDA) is actively under review, with anticipation building for formal authorization. In a bold move to secure global intellectual property protection, CSDX has simultaneously initiated patent filings for CS-Protect Hydrogel in the USA, Europe, the UAE, and six additional strategic countries. This proactive strategy ensures the product is primed for swift commercialization upon FDA approval, positioning CSDX at the forefront of cutting-edge hydrogel technology.
Meanwhile, MEDUSA - CSDX's revolutionary protective solution - has achieved full authorization in both the UAE and Europe, marking a major victory in its international rollout. The product's application with the U.S. Environmental Protection Agency (EPA) continues to progress under review. Manufactured by Gulf Centre Group (CGCE) in the United Arab Emirates under the ownership of CS Interpharm General Trading, MEDUSA is experiencing surging demand from key sectors including hospitals, hotels, and schools. This momentum has propelled a staggering
Building on this momentum, CSDX is gearing up to launch its Regulation D offering, initially announced in August 2025. Thanks to the dedicated efforts of the team, the offering is on track to go live in the coming days. This pivotal capital raise will fuel the acceleration of CS-Protect Hydrogel and MEDUSA into the U.S. and other global markets, while bolstering the Company's sales force and amplifying marketing initiatives to meet ambitious growth forecasts.
In a further commitment to transparency and governance, CSDX expects to become a fully Securities and Exchange Commission (SEC)-reporting company by the end of September 2025. The Company will also take immediate steps to consolidate the financials of its group of companies, providing stakeholders with a clearer, more unified view of its robust performance.
These initiatives reflect CSDX's unwavering dedication to delivering value to shareholders and revolutionizing the diagnostics and protection landscape. With regulatory hurdles clearing and market demand soaring, CSDX is on the cusp of unprecedented success.
*About CS Diagnostics Corp.*
CS Diagnostics Corp. (OTCQB: CSDX) is a dynamic company focused on developing and commercializing advanced diagnostic tools and protective solutions for healthcare, hospitality, and educational sectors worldwide. Headquartered in Cheyenne, Wyoming, CSDX leverages innovation and strategic partnerships to drive growth and improve outcomes across global markets.
For further information please visit https://csdcorp.us
or contact Investor Relations at info@csdcorp.us
*Forward-Looking Statements*
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
Actual results achieved may vary from the information provided herein because of numerous known and unknown risks, uncertainties, and other factors.
SOURCE: CS Diagnostics Corp.
View the original press release on ACCESS Newswire
FAQ
What regulatory approvals has CSDX received for MEDUSA in 2025?
How much revenue growth did CSDX's subsidiary CSI report in 2025?
When will CSDX begin shipping MEDUSA to the European market?
What is the status of CS-Protect Hydrogel's FDA application?
When will CSDX become an SEC-reporting company?
